The pan-PI3K inhibitor buparlisib was evaluated in combination with paclitaxel in a phase II trial for the treatment of recurrent or metastatic HNSCC patients, demonstrating manageable safety profile and preliminary anti-HNSCC activity [14]. Here, PIK3CA is linked to head and neck squamous cell carcinoma.